BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Stoke Therapeutics

Stoke Therapeutics logo

Founded
2014
Patents
12
Clinical Trials
2

Technologies

Antisense Oligonucleotides

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.

Become a Member to view additional information about this company

Posts Mentioning This Company